Opinion of the Transparency Council – mycophenolas mofetil
At its meeting on 14 October 2024, the Transparency Council adopted opinion No. 165/2024 on the inclusion in reimbursement of medicines containing the active substance mycophenolas mofetil in terms of indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics